» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

COG-D9902

Trial

Clinical Trial Title

Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma

Trial Status

Closed to Enrollment

Start Date

October 25, 2005

Trial Type

Pediatric Cancer (Oncology)

Specific Condition

Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), Unclassified soft tissue sarcoma, and Other soft tissue neoplasms (excluding benign tumors).

Description

A COG soft tissue sarcoma diagnosis, biology and banking protocol.

Patients enrolled on D9902 fall into one of three groups:

Category 1: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review stratum of D9902.

Category 2: Patients planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can be enrolled on the Central Review and Biology/Banking strata of D9902.

Category 3: Patients NOT planning to be enrolled on a front-line COG RMS or NRSTS therapeutic study can only enroll on the Biology/Banking stratum of D9902. Pathology Central Review will not be performed for clinical purposes or to meet any of the research objectives, except to establish the bank. The enrolling investigator/institution will not receive a report back from COG regarding the submitted sample.

Eligibility Criteria

Age: patients must be < 50 years of age at the time of enrollment

Patients must have one of the following histologically-confirmed diagnoses: Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), unclassified soft tissue sarcoma that is too undifferentiated to be placed in a specific pathologic category in the WHO classification, and other soft tissue neoplasms, excluding benign tumors

Patients with malignant rhabdoid tumor, Ewing sarcoma/PNET, or ostogenic sarcoma of bone are NOT eligible for enrollment on D9902

Notes

https://clinicaltrials.gov/ct2/show/NCT00919269

Study status is:
Completed: The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Principal Investigator Name

Janice Olson, MD

Contact Name

Children's Cancer and Blood Disorders Program

Phone

(503) 276-9300

Last Updated: Wednesday, January 27, 2021 11:41:32 AM